17854040|t|Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
17854040|a|This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients. Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients. The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients. HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL). Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients. To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients. The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively. It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.
17854040	26	36	lamivudine	ChemicalEntity	D019259
17854040	66	98	hepatitis B virus (HBV) infected	DiseaseOrPhenotypicFeature	D006509
17854040	99	107	patients	OrganismTaxon	9606
17854040	125	141	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
17854040	186	209	HBV and HIV co-infected	DiseaseOrPhenotypicFeature	D006509,D015658
17854040	224	232	patients	OrganismTaxon	9606
17854040	279	289	lamivudine	ChemicalEntity	D019259
17854040	300	317	hepatitis B virus	OrganismTaxon	10407
17854040	319	322	HBV	OrganismTaxon	10407
17854040	344	354	lamivudine	ChemicalEntity	D019259
17854040	362	365	HBV	OrganismTaxon	10407
17854040	392	439	human immunodeficiency virus (HIV) co-infection	DiseaseOrPhenotypicFeature	D015658
17854040	457	465	patients	OrganismTaxon	9606
17854040	479	489	lamivudine	ChemicalEntity	D019259
17854040	497	509	HBV infected	DiseaseOrPhenotypicFeature	D006509
17854040	510	518	patients	OrganismTaxon	9606
17854040	535	551	HIV co-infection	DiseaseOrPhenotypicFeature	D015658
17854040	577	594	HBV mono-infected	DiseaseOrPhenotypicFeature	D006509
17854040	595	603	patients	OrganismTaxon	9606
17854040	611	630	HBV-HIV co-infected	DiseaseOrPhenotypicFeature	D006509,D015658
17854040	631	639	patients	OrganismTaxon	9606
17854040	697	700	HBV	OrganismTaxon	10407
17854040	702	707	HBsAg	ChemicalEntity	D006514
17854040	730	733	HBV	OrganismTaxon	10407
17854040	735	740	HBsAg	ChemicalEntity	D006514
17854040	752	760	patients	OrganismTaxon	9606
17854040	762	767	HBsAg	ChemicalEntity	D006514
17854040	798	805	HIV 1/2	OrganismTaxon	11676,11709
17854040	950	953	HBV	OrganismTaxon	10407
17854040	1137	1140	HBV	OrganismTaxon	10407
17854040	1152	1155	HBV	OrganismTaxon	10407
17854040	1195	1198	HBV	OrganismTaxon	10407
17854040	1257	1260	HBV	OrganismTaxon	10407
17854040	1261	1271	lamivudine	ChemicalEntity	D019259
17854040	1337	1348	hepatitis B	DiseaseOrPhenotypicFeature	D006509
17854040	1349	1357	patients	OrganismTaxon	9606
17854040	1371	1390	HBV-HIV co-infected	DiseaseOrPhenotypicFeature	D006509,D015658
17854040	1391	1399	patients	OrganismTaxon	9606
17854040	1468	1471	HBV	OrganismTaxon	10407
17854040	1472	1482	lamivudine	ChemicalEntity	D019259
17854040	1519	1538	HBV-HIV co-infected	DiseaseOrPhenotypicFeature	D006509,D015658
17854040	1539	1547	patients	OrganismTaxon	9606
17854040	1553	1556	HBV	OrganismTaxon	10407
17854040	1603	1611	patients	OrganismTaxon	9606
17854040	1811	1814	HBV	OrganismTaxon	10407
17854040	1838	1848	lamivudine	ChemicalEntity	D019259
17854040	2031	2050	HBV-HIV co-infected	DiseaseOrPhenotypicFeature	D006509,D015658
17854040	2051	2059	patients	OrganismTaxon	9606
17854040	Association	D019259	D015658	No
17854040	Negative_Correlation	D019259	D006509	No